| INTRODUC TI ON
Irritable bowel syndrome (IBS) affects 10%-15% of people worldwide, is a leading cause of work absenteeism, and consumes 0.5% of the annual healthcare budget. 1 Irritable bowel syndrome is a functional disorder described according to expert consensus (Rome)
criteria, based on the presence of symptoms of abdominal pain and bloating associated with constipation (IBS-C), diarrhea (IBS-D), or both (IBS-M).
2, 3 The pathophysiology of IBS is poorly understood, although a number of factors have been proposed to contribute including visceral hypersensitivity and altered motility, dysregulated immune activation, miscommunication along the gut-brain axis, bile acid malabsorption, food intolerance, and gut microbiota dysbiosis. 4 In the absence of informative diagnostic tests, increasing hope has been put into genetic studies for the identification of biomarkers and actionable biological pathways that may be exploited for therapeutic purposes. 4 A heritable component of IBS is long recognized in family and twin studies, 5 and more recently in a nationwide survey of the Swedish population where increased risk was detected among first, second, and third degree relatives of IBS probands. 6 Through candidate gene studies, we have shown that 2%-3% of IBS patients carry rare functional SI and SCN5A mutations that may link these phenotypes to carbohydrate malabsorption and channelopathies, respectively. 7, 8 In addition, associations with common single nucleotide polymorphisms (SNPs) have been reported and replicated for the genes TNFSF15, TRPM8, CDC42, and NPSR1 (and SI and SCN5A)
by our group and others. [9] [10] [11] [12] [13] [14] Yet, IBS gene-hunting efforts have been mostly underpowered to capture modest genetic risk effects, and no unequivocal IBS risk locus has been thus far identified. Despite its described heritability, adequate large-scale hypothesis-free genome-wide association studies (GWAS) have not been reported, possibly because of the lack of suitably sized clinical cohorts with available genetic data.
Because of its high prevalence, we recently hypothesize that a powerful approach to study IBS predisposition may come from the survey of large population-based cohorts, where existing genetic and epidemiological data may be exploited with considerable gain in sample homogeneity and size. 15 Exploiting genotype and questionnaire (Rome Criteria) data available for the TwinGene subset of the Swedish Screening Across Lifespan Twin survey, 16 we recently carried out a pilot population-based GWAS of IBS, where we identified a suggestive signal of association for the KDLR2/GRID2IP region on chromosome 7p22.1 that could be independently replicated in IBS cases and controls from tertiary centers. 17 Here, we report a meta-analysis of IBS GWAS results from
TwinGene and 4 additional population-based cohorts, which a computational pipeline exploiting ontology and interaction networks, and tissuespecific and gene set enrichment analyses. 
Conclusion & Inferences:
Our results confirm the feasibility of population-based studies for gene-discovery efforts in IBS, identify risk genes and loci to be prioritized in independent follow-ups, and pinpoint ion channels as important players and potential therapeutic targets warranting further investigation.
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Key Points
• The pathophysiology of irritable bowel syndrome (IBS) is complex and still poorly understood. A heritable component is long known in IBS but gene-hunting efforts have so far been scarce and no unequivocal IBS risk locus has yet been identified. Here, we report genome-wide association studies (GWAS) and their meta-analysis in 5
population-based cohorts.
• Seven genomic regions, harboring 64 candidate genes were detected. Functional annotation of this gene set highlighted regulation of ion channel activity as the most plausible pathway affecting IBS risk.
• The results support the hypothesis of ion channel in- 
| ME THODS

| Study cohorts
Genotype and questionnaire-based epidemiological data from 5
large population cohorts, all previously described in detail, were included in this study. The demographics are reported in Table 1 , while a short description of each study cohort and respective criteria for defining IBS cases and controls follows below. All participants provided informed consent, the study protocols were approved by the respective local ethics review boards (see individual cohort information below) and all methods were performed in accordance with the relevant guidelines and regulations.
| TwinGene
TwinGene is a subset of the Screening Across the Lifespan Twin
Study initiated in 1998, and focused on twins born in 1958 or before. 16, 18 Most of these individuals (n = 45 750, 72.5%) participated in telephone interviews where, among others, GI symptoms were recorded using an adapted version of the Rome criteria module, thoroughly described elsewhere. 19 Genotyping of 9741 individuals from this cohort was performed using Illumina HumanOmniExpress arrays, and TwinGene IBS GWAS results have been previously published. 17 The study was approved by Karolinska Institutet's Ethics Review Board.
| LifeLines-DEEP (LLD)
LifeLines is a large population-based cohort initiated in 2006 in the 
| SHIP-Trend
| TwinsUK
| Nfbc1966
The TA B L E 1 Demographics of cohorts included in the meta-analysis were available for 4098 NFBC1966 participants, and were used in this study. NFBC1966 participants gave their informed consent and the Regional Ethics Committee of the Northern Ostrobothnia District approved the study.
| Genotype quality control (QC) and individual
GWA studies
Genotype 
| GWAS meta-analysis
Prior to meta-analysis, individual GWAS association results was checked by using the R package EasyQC (v9.2) in order to identify study-specific problems, remove missing/invalid data or duplicates, and harmonize allele coding among datasets. 27 The absence of population stratification was controlled for based on the genomic control inflation factor (λ < 1.10 for all cohorts). All GWAS results were filtered for SNP markers with minor allele frequency (MAF) >0.01
and imputation quality score (INFO > 0.8) before meta-analysis. A total of 2 483 385 high-quality SNP markers passing QC, with available summary statistics from at least 2 datasets, and the absence of heterogeneity across studies (Cochran's Q > 0.05) were brought forward into the meta-analysis. Meta-analysis was performed with the statistical software METAL using the fixed-effect method weighted by inverse variance.
28
Manhattan plots were generated with the R package 
| Post-GWAS functional genomics analyses
The IBS risk loci were defined as non-overlapping genomic regions extending ±250 Kb from (suggestive) association signals with P ≤ 5.0 × 10 −6 . Annotation of genes mapping to the identified risk loci was performed based on risk loci genomic coordinates using the XGR package. 31 The IBS risk loci were examined for quantitative ciseffects over gene expression levels (eQTLs) by screening the publicly 
| RE SULTS
| Computational strategy
We implemented a bioinformatic pipeline for a step-wise analysis of collected data, foreseeing (1) data quality control (QC) and single GWAS from individual cohorts, (2) harmonization and meta-analysis of GWAS results, and (3) functional annotation of the identified risk regions in order to gain biological insight from the observed associations. A schematic summary of this strategy is reported in Table 2 , together with the computational tools and protocols adopted for the respective analyses.
| GWAS meta-analysis
Based on questionnaire data from genotyped participants in individ- ) association signals, which also showed concordance of genetic risk effects in individual cohorts ( Table 3 ). The strongest association signal was obtained for the marker rs17112758 on chromosome 1 (P = 1.89 × 10 −6
), in a region where the phospholipid phosphatase 3 (PLPP3) gene maps.
| Downstream analyses of suggestive IBS risk loci
Based on a computational annotation of gene content and gene expression from respective regions (see Methods and Table 2 ), IBS risk loci were predicted to harbor 35 genes and several SNPs affecting the expression of 29 additional nearby genes (expression quantitative trait loci-eQTL; Table 3 ), thus bringing the total number of transcripts of interest to 64.
Tissue-specific enrichment analysis (TSEA) of expression in different human tissues indicated nominally significant higher expression of these genes in the colon compared to other sites (P = 0.027).
An ontology-based GSEA using the risk gene set for functional class scoring (see Methods and Table 2 ) significance levels are indicated, respectively, with red and blue horizontal dashed lines. For each suggestive association signal, the nearest gene (mapping closest to the lead SNP) is reported, together with the number of additional genes from the same locus (in brackets) 
TA B L E 3 GWAS meta-analysis results
Lead
| IBS risk genes from previous studies
Meta-analysis results were also inspected specifically at loci previously proposed to affect risk of IBS and/or its intermediate phe-
notypes-colonic transit, abdominal pain, and sensory ratings.
15 Table 4 reports meta-analysis summary statistics corresponding
F I G U R E 2 Gene set enrichment analysis results. Top Gene Ontology terms (Molecular Function and Biological Process) and Molecular
Signature Database sets are ranked by adjusted P-value after FDR correction (the dotted line indicates cut-off significance at P = 0.05) CHR: chromosome; EA: effect allele; EAF: effect allele frequency. a Best association signal (lowest P-value) from the region containing the coding sequence + 2 kb each side. Significant associations (P ≤ 0.05) are highlighted in bold.
to genes and loci selected based on prior IBS associations from existing literature. We observed nominal association for at least one SNP marker in 12 of 18 inspected loci, with best evidence of replication for the genes SCN5A, SI, NPSR1, and TRPM8, as well the 7p22.1 KDELR2/GRID2IP region from our previous IBS GWAS (Table 4) .
| D ISCUSS I ON
We report here a GWAS meta-analysis of 5 IBS studies from general population-based cohorts totaling 18 659 individuals, and including 1335 cases and 9768 asymptomatic controls. We report suggestive genes cannot be singled out at this stage, although it is interesting to note that these 2 regions harbor, respectively, the G protein-coupled receptor 88 (GPR88) playing a role in the regulation of cognitive and motor function, and a cluster of ion channel genes including SCN1B and the FXYD family, which are involved in the control of smooth muscle excitability (discussed more in detail below).
Our downstream functional (GSEA) analysis of the suggestive GWAS loci yielded statistically sound, compelling evidence that the corresponding IBS risk gene pool is enriched for transcripts involved in the regulation of ion channel activity (sodium channel regulator activity and regulation of sodium ion transmembrane transporter activity were the highly significant, top-ranking GO terms for the classes molecular function and biological process, respectively). This finding is noteworthy, as it replicates and reinforces our previous observations that DNA variations affecting ion channel function(s) result in detectable genetic risk effects in IBS and its intermediate phenotypes. 7, 11, 35 Indeed, rare variants and common SNPs affecting IBS risk have been identified in the ion channel genes SCN5A (coding for the voltage-gated sodium channel NaV1.5 associated with various forms of arrhythmia including Brugada syndrome) 36 and TRPM8
(coding for the "cold-" and menthol-receptor transient receptor potential cation channel subunit M member 8), 11 while recent GWAS results highlighted ion channel activity and xenobiotic metabolism among the biological pathways most relevant to stool frequency (metabolism and xenobiotics being a molecular signature identified also here through GSEA downstream analysis of GWAS results).
35
Ion channels are located in the membranes of all types of cells and coordinate ion passage across membranes in response to different stimuli. 37 They have also cell-specific functions and, particularly in the gut, they play important roles in GI functions relevant to IBS, such as secretion and absorption of electrolytes and fluids, hormone secretion, control of motility and visceral sensation through neuronal signaling, and induction of smooth muscle contraction. [38] [39] [40] [41] Dysfunctional ion channels can lead to conditions known as channelopathies, which indeed most often develop because of deleterious mutations in the corresponding genes. Channelopathies are well known in the fields of cardiology and neurology, contributing to several complex conditions including cardiac arrhythmias and painrelated neuropathies. [42] [43] [44] In these conditions, patients often report bowel complaints, and this has led to the hypothesis that specific ion channels may also be relevant to IBS. 45 Our meta-analysis results were also investigated in relation to previously reported IBS candidate risk genes (Table 4) , and nominal replication (P ≤ 0.05) was obtained for 12 of 18 tested loci. While borderline associations may be more difficult to properly evaluate, best association signals (lowest P-values) were detected for the KDELR2/GRID2IP locus on chromosome 7 and the genes TRPM8, SCN5A, NPSR1, and SI (Table 4 ). This result may be expected for the first 3 loci, which were already detected in the original TwinGene GWAS 17 that contributes 43% of the variance to the current meta-analysis, although NPSR1 and SI signals may represent bona fide replications. NPSR1 (neuropeptide S receptor gene) is a neuropeptide receptor involved in anxiety, inflammation, and nociception, and we previously reported its association with colonic transit and sensory ratings in IBS patients, 13 and recurrent abdominal pain in Swedish children from a population-based birth cohort. 14 The SI gene codes for sucrase-isomaltase, an intestinal disaccharidase that digests 60% of dietary starch and sucrose and is mutated in patients suffering from congenital sucrase-isomaltase deficiency (CSID, also called sucrose intolerance). This condition is due to colonic accumulation of undigested carbohydrates that provoke symptoms largely overlapping with those observed in IBS patients (CSID is also sometimes misdiagnosed as IBS), and we recently demonstrated that functional SI variants with reduced SI enzymatic activity associate with increased risk of IBS, particularly IBS-D. 8 Replicating SI associations with IBS in a population-based sample is, therefore, a noteworthy finding from this study. Weaker replication signals, for instance in the IBS risk (immune-related) gene TNFSF15 consistently replicated in independent case-control studies after our original identification, 9,10,12 may be due to dilution of specific (immune-mediated) genetic risk effects when assessing associations with IBS solely defined based on questionnaire data.
In conclusion, we report a meta-analysis of 5 independent IBS GWA studies including a total of 1335 patients and 9768 asymptomatic controls. Its outcome demonstrates the feasibility of populationbased approaches to gene discovery in IBS, identifies 7 candidate risk loci to prioritize in follow-up validation efforts, and highlights the biology of ion channels as a plausible IBS pathophysiological pathway that warrants further investigation.
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